Cabrera-Rode Eduardo, Loaiza-Romero Brayam Javier, Rodríguez-Acosta Janet, Cubas-Dueñas Ileana, Hernández-Rodríguez José, Díaz-Díaz Oscar
EC: Biol. Ph. D. Ciencias Biológicas, Universidad de la Habana. Instituto de Endocrinología (INEN), Universidad de Ciencias Médicas de la Habana. La Habana, Cuba.
BL: MD. Esp. Endocrinología. Instituto de Endocrinología (INEN), Universidad de Ciencias Médicas de la Habana. La Habana, Cuba.
Rev Salud Publica (Bogota). 2023 Nov 1;25(6):110831. doi: 10.15446/rsap.V25n6.110831. eCollection 2023 Dec.
To determine the usefulness of the hypertension-abdominal obesity phenotype as an indicator of dysglycaemia and insulin resistance.
Cross-sectional descriptive study of 964 adults (449 women and 515 men) who attended the Institute of Endocrinology with risk of tus. Demographic (age, sex, skin colour), clinical (blood pressure and acanthosis nigricans), anthropometric (weight, height, waist circumference and body mass index) and laboratory (basal and oral glucose tolerance test-stimulated blood glucose and insulinaemia) variables were analysed. The insulin resistance index was calculated. The abdominal hypertension-obesity phenotype was defined as the presence of systolic pressure ≥130 mm Hg and/or diastolic pressure ≥80 mm Hg or treated hypertension, waist circumference ≥80 cm in women and ≥90 cm in men. Sensitivity, specificity and predictive values of the abdominal obesity hypertension phenotype were calculated to identify dysglycaemia and insulin resistance.
Individuals with the hypertension-abdominal obesity phenotype showed a higher proportion of impaired glucose metabolism and insulin resistance than those without the phenotype (p<0.0001). The hypertension-abdominal obesity phenotype better identifies persons with the presence of double prediabetes, and insulin resistance, as they show high sensitivities (85.9%, 77.5%, and 68.9%, respectively), and high negatives predictive values (97.9%, 95.8%, and 74.0%, respectively).
The hypertension-abdominal obesity phenotype is a simple, useful option for identifying persons with dysglycaemia, and insulin resistance.
确定高血压-腹型肥胖表型作为血糖异常和胰岛素抵抗指标的实用性。
对964名有tus风险且前往内分泌研究所就诊的成年人(449名女性和515名男性)进行横断面描述性研究。分析了人口统计学(年龄、性别、肤色)、临床(血压和黑棘皮病)、人体测量学(体重、身高、腰围和体重指数)以及实验室(基础和口服葡萄糖耐量试验刺激后的血糖和胰岛素血症)变量。计算胰岛素抵抗指数。腹型高血压-肥胖表型定义为收缩压≥130 mmHg和/或舒张压≥80 mmHg或患有高血压,女性腰围≥80 cm,男性腰围≥90 cm。计算腹型肥胖高血压表型用于识别血糖异常和胰岛素抵抗的敏感性、特异性和预测值。
具有高血压-腹型肥胖表型的个体相比无该表型的个体,糖代谢受损和胰岛素抵抗的比例更高(p<0.0001)。高血压-腹型肥胖表型能更好地识别患有双重糖尿病前期和胰岛素抵抗的人群,因为它们显示出高敏感性(分别为85.9%、77.5%和68.9%)以及高阴性预测值(分别为97.9%、95.8%和74.0%)。
高血压-腹型肥胖表型是识别血糖异常和胰岛素抵抗人群的一种简单且有用的方法。